Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and ...

Divi's Laboratories, India's largest API (Active Pharmaceutical Ingredient) manufacturer, sits amid a changing landscape within the global pharmaceutical universe. The growth levers for Divi’s are ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...

La société indienne Divi's Laboratories a annoncé lundi un bénéfice trimestriel supérieur aux prévisions, grâce aux bonnes performances de son activité de production sur mesure de composés chimiques ...

Nov 7 (Reuters) - Indian drugmaker Divi's Laboratories (DIVI.NS), opens new tab reported second-quarter profit above analysts' estimates on Friday, helped by its business that focuses on customised ...

As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the structural China+1/BIOSECURE-linked tailwind, analysts believe.

The pharmaceutical industry has been traditionally slow in embracing new technologies, but Divi’s Laboratories is showing the way forward. Recently, this Hyderabad-based firm zeroed in on Juniper ...

Le laboratoire pharmaceutique indien Divi's Laboratories a annoncé vendredi des bénéfices supérieurs aux attentes des analystes pour le deuxième trimestre, soutenus par son activité de production ...

Divi's Labs reported its Q1 results on August 3. Pharma company Divi's Laboratories announced plans to foray into peptide fragment molecules, advancing from the peptide building blocks it currently ...

The FDA, which last month banned APIs coming from a Divi’s Laboratories plant in India, has followed that up with a warning letter that savages the facility for refusing to give inspectors records ...